Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children with Generalized Myasthenia Gravis
The purpose of this trial is to evaluate the long-term safety of efgartigimod IV and efgartigimod PH20 SC administered to participants with gMG in the antecedent studies, ARGX-113-2006 and ARGX-113-2207, respectively.
Generalized Myasthenia Gravis
BIOLOGICAL: Efgartigimod IV or Efgartigimod PH20 SC
Incidence of adverse events (AEs), up to 4 years|Severity of adverse events (AEs), up to 4 years|Incidence of serious adverse events (SAEs), up to 4 years|Severity of serious adverse events (SAEs), up to 4 years|Incidence of adverse events of special interest (AESIs), up to 4 years|Severity of adverse events of special interest (AESIs), up to 4 years|Changes in height from baseline, up to 4 years|Changes in weight from baseline, up to 4 years|Electrocardiogram - heart rate, up to 4 years|Electrocardiogram - QTcF (ms), up to 4 years
Incidence of antidrug antibodies (ADAs) against efgartigimod, up to 4 years|Prevalence of antidrug antibodies (ADAs) against efgartigimod, up to 4 years|Incidence of antibodies against recombinant human hyaluronidase PH20 (rHuPH20), Up to 4 years|Prevalence of antibodies against recombinant human hyaluronidase PH20 (rHuPH20), Up to 4 years
The purpose of this trial is to evaluate the long-term safety of efgartigimod IV and efgartigimod PH20 SC administered to participants with gMG in the antecedent studies, ARGX-113-2006 and ARGX-113-2207, respectively.